Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series
Year: 2025
Type: article
Study design: Case Report
Abstract: Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy (ICE) score for the assessment and monitoring of ICANS. Objective: To demonstrate modifications to ICE score to patients with vision and hearing impairments or who are who are from non-native-speaking backgrounds. Methods: We discuss five cases and the modifications made to adapt the ICE score to meet patients' needs. Results: Modifications to ICE score was feasible and it assisted with CAR T cell therapy outcome monitoring. Discussion: These cases highlight the need for flexible and patient-tailored strategies and the importance of collaboration between multidisciplinary teams and patients' families/caregivers when monitoring patients for ICANS after CAR T-cell therapy.
Source: BMJ Neurology Open
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: Eli Lilly and Company, AstraZeneca, Gilead Sciences, Biogen, Royal Melbourne Hospital Neuroscience Foundation, LivaNova, Australian Government, BeiGene, Multiple Sclerosis Australia, University of Melbourne, Eisai, Dementia Australia, Medical Research Council, National Health and Medical Research Council, National Institute of Neurological Disorders and Stroke, UCB Pharma
OpenAlex ID: W4407405316